Nexgel Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
49.1%projected annual EPS growth
Analyst Coverage
1analyst covering
FY EPS (est.)
-$0.12next fiscal year
Monitoring Framework
Key Performance Indicators
Quarterly Revenue Quarterly2.7M
Annual Pro-Forma Revenue Target Annually11.4M
Gross Profit Margin Quarterly40.0%
Watch Items
- Integration of Celularity Regenerative Biomaterial AssetsTrigger: Delays in pro-forma revenue scaling or supply chain disruptions with Sequence LifeScienceAction: Re-evaluate pro-forma revenue targets and assess contract manufacturing efficiency
- Going Concern and Liquidity StatusTrigger: Unrestricted cash falling below $500,000 without additional financingAction: Review cash burn rate, monthly operating overhead of $500,000, and capital raising options
- Surgical Division Sales Force Ramp-upTrigger: Dave Hazard failing to secure key enterprise partnerships or white-label agreementsAction: Assess sales strategy for BioNX Surgical and review distribution channels
Research as of 20 Jun 2026